| Literature DB >> 29338684 |
Shiqun Chen1,2,3, Yong Liu1,3, Sheikh Mohammed Shariful Islam3, Hua Yao1, Yingling Zhou1,2, Ji-Yan Chen4, Qiang Li3.
Abstract
BACKGROUND: A simple noninvasive model to predict obstructive coronary artery disease (OCAD) may promote risk stratification and reduce the burden of coronary artery disease (CAD). This study aimed to develop pre-procedural, noninvasive prediction models that better estimate the probability of OCAD among patients with suspected CAD undergoing elective coronary angiography (CAG).Entities:
Keywords: Framingham risk; Obstructive coronary artery disease; Prediction model
Mesh:
Substances:
Year: 2018 PMID: 29338684 PMCID: PMC5771201 DOI: 10.1186/s12872-018-0745-0
Source DB: PubMed Journal: BMC Cardiovasc Disord ISSN: 1471-2261 Impact factor: 2.298
Baseline characteristics of patients without and those with obstructive coronary artery disease
| Variables | No (%) of patients with available data | Subjects without | Subjects with | |
|---|---|---|---|---|
| Demographic | ||||
| Age | 1262(100) | 62.0 ± 10.4 | 64.2 ± 10.2 | < 0.001 |
| Gender, men | 1262(100) | 181(57.1%) | 693(73.3%) | < 0.001 |
| Signs and measurement | ||||
| Heart rate, beats/min | 1261(99.9) | 73.4 ± 11.3 | 72.9 ± 11.9 | 0.49 |
| Systolic BP, mm Hg | 1262(100) | 131.9 ± 17.9 | 132.7 ± 18.6 | 0.54 |
| Diastolic BP, mm Hg | 1262(100) | 78.3 ± 12 | 77.5 ± 11.6 | 0.32 |
| Weight, kg | 1257(99.6) | 63.5 ± 9.5 | 65.2 ± 10.9 | 0.01 |
| Medical history | ||||
| Smoking | 1262 (100) | 80(26.2%) | 347 (36.7%) | < 0.001 |
| Hypertension | 1262(100) | 152(48.0%) | 615 (65.1%) | < 0.001 |
| Congestive heart failure | 1262(100) | 19(6.5%) | 79 (8.4%) | 0.29 |
| Diabetes mellitus | 1260(99.8) | 51(16.1%) | 259 (27.5%) | < 0.001 |
| Hyperlipidemia | 1262(100) | 42(13.3%) | 144 (15.2%) | 0.75 |
| Anemia | 1262(100) | 79(25.2%) | 349 (37.5%) | < 0.001 |
| Medications | ||||
| ACEI/ARB | 1262(100) | 240(75.7%) | 864(89.5%) | < 0.001 |
| Diuretics | 1261(99.9) | 36(11.4%) | 91(9.6%) | 0.38 |
| β-blocker | 1262(100) | 244(76.9%) | 853(90.0%) | < 0.001 |
| Statin | 1262(100) | 279 (88.0%) | 912(96.5%) | < 0.001 |
| Calcium-channel blocker | 1259(99.8) | 60(19.0%) | 198(21.0%) | 0.44 |
| Physical examination | ||||
| LVEF, % | 1013(80.3) | 64.6 ± 11 | 61.4 ± 11.9 | < 0.001 |
| Laboratory measures | ||||
| Total cholesterol, mg/dl | 1262(100) | 168.2 ± 38.8 | 172.6 ± 64.6 | 0.15 |
| HDL-C,mg/dl | 1262(100) | 40 ± 10.8 | 36.8 ± 10.3 | < 0.001 |
| Triglyceride, μmol/l | 1262(100) | 2.3 ± 11.8 | 1.6 ± 1.4 | 0.27 |
| LDL cholesterol, μmol/l | 1262(100) | 2.5 ± 0.8 | 2.6 ± 0.9 | 0.19 |
| Lp (a), μmol/l | 1081(85.7) | 211.4 ± 231.1 | 287.2 ± 311.4 | < 0.001 |
| Blood urea nitrogen, mg/dl | 1246(98.7) | 4.7 ± 1.6 | 5.2 ± 2.3 | < 0.001 |
| Serum Creatinine, μmol/l | 1261(99.9) | 78.0 ± 29.6 | 89.7 ± 50.7 | < 0.001 |
| Hemoglobin, g/ml | 1246(100) | 135.1 ± 15.1 | 133.3 ± 16.0 | 0.0929 |
| Serum albumin, g/l | 1220(96.7) | 36.9 ± 4.1 | 36.1 ± 3.9 | 0.0035 |
| Urine PH | 1213(96.1) | 5.9 ± 0.7 | 6.0 ± 0.7 | 0.48 |
| HbA1c, % | 1043(82.6) | 6.3 ± 1.1 | 6.5 ± 1.2 | 0.006 |
| Hs-CRP, mmol/l | 849(67.3) | 3.8 ± 5.7 | 6.6 ± 13.0 | < 0.001 |
| Uric acid, mmol/l | 994(78.8) | 364.6 ± 92.7 | 389.3 ± 102.5 | < 0.001 |
| B-type natriuretic peptide, pg/m | 1041(82.5) | 609.4 ± 2061.0 | 772.4 ± 2289.0 | 0.29 |
LVEF = left ventricular ejection fraction; ACEI/ARB = angiotensin-converting enzyme inhibitor/angiotensin receptor blocker; HDL-C = high-density lipoprotein cholesterol; LDL-C = low-density lipoprotein-cholesterol; HbA1c = glycated hemoglobin; Hs-CRP = high-sensitivity C-reactive protein
Univariate analyses and multivariate associations between variables and obstructive coronary artery disease
| Risk factors | Univariate logistic regressiona | Multivariate logistic regressionb | ||||
|---|---|---|---|---|---|---|
| OR | 95% CI | P value | OR | 95% CI | P value | |
| Age, (per year) | 1.11 | 1.04–1.18 | < 0.01 | 1.02 | 1.00–1.04 | 0.05 |
| Gender (male vs. female) | 2.07 | 1.56–2.69 | < 0.01 | 2.99 | 1.97–4.45 | < 0.01 |
| Hypertension (yes vs. no) | 2.02 | 1.56–2.62 | < 0.01 | 1.72 | 1.17–2.55 | < 0.01 |
| Anemia (yes vs. no) | 1.78 | 1.33–2.37 | < 0.01 | 1.76 | 1.14–2.72 | < 0.01 |
| LVEF (per %) | 0.97 | 0.96–0.99 | < 0.01 | 0.98 | 0.96–1.00 | < 0.01 |
| Hs-CRP (per mmol/l) | 1.04 | 1.01–1.07 | < 0.01 | 1.03 | 1.00–1.05 | 0.07 |
| TC (per 10 mg/dl) | 1.02 | 0.99–1.05 | 0.25 | 1.06 | 1.01–1.11 | 0.03 |
| HDL-C (per mg/dl) | 0.97 | 0.96–0.99 | < 0.01 | 0.98 | 0.96–0.99 | < 0.01 |
OR: odds ratio; CI: confidence interval; LVEF = left ventricular ejection fraction; Hs-CRP = high-sensitivity C-reactive protein; TC: total cholesterol; HDL-C = high-density lipoprotein cholesterol
aUnivariate logistic regression analysis was performed in 1262 patients
bMultivariate logistic regression analysis was performed in 683 patients without missing data of the variables in the final model
Modified Framingham risk factor and Framingham risk factor model fitting
| Model | AUC | AIC | HLG | P value |
|---|---|---|---|---|
| Modified Framingham risk factors | 0.719 | 691 | 0.38 | Reference |
| Framingham risk factors | 0.693 | 705 | 0.35 | 0.059 |
| Modified Framingham score | 0.703 | 689 | 0.43 | Reference |
| Framingham score | 0.521 | 753 | 0.03 | < 0.001 |
AUC: area under the curve; AIC: Akaike information criterion; HLG: Hosmer and Lemeshow goodness-of-fit test
Fig. 1Bimodal Modified Framingham scoring (MFS) distribution
Fig. 2Receiver operating characteristic curve
Fig. 3OCAD prevalence according to modified Framingham score
Fig. 4Scheme to define OCAD risk score